{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:17:39Z","timestamp":1790727459827,"version":"4.1.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10787-025-01871-2","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T08:43:48Z","timestamp":1754642628000},"page":"4477-4498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chemokine receptor type-5: a key regulator of immunity, disease pathogenesis, and emerging therapeutic target"],"prefix":"10.1007","volume":"33","author":[{"given":"Vaishali","family":"Bambal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Kodihalli Basavaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1325-9367","authenticated-orcid":false,"given":"Kenchappa","family":"Vanaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"1871_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100083","volume":"4","author":"N Agresti","year":"2021","unstructured":"Agresti N, Lalezari JP, Amodeo PP, Mody K, Mosher SF, Seethamraju H, Kelly SA, Pourhassan NZ, Sudduth CD, Bovinet C, ElSharkawi AE, Patterson BK, Stephen R, Sacha JB, Wu HL, Gross SA, Dhody K (2021) Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab. J Transl Autoimmun 4:100083. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100083","journal-title":"J Transl Autoimmun"},{"issue":"9","key":"1871_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107389","volume":"9","author":"B Aiamkitsumrit","year":"2014","unstructured":"Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher MR, Pirrone V, Ivanova T, Zhong W, Kilareski E, Aldigun H, Frantz B, Rimbey M, Wojno A, Passic S, Williams JW, Shah S, Blakey B, Parikh N, Jacobson JM, Moldover B, Wigdahl B (2014) Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences. PLoS ONE 9(9):e107389. https:\/\/doi.org\/10.1371\/journal.pone.0107389","journal-title":"PLoS ONE"},{"issue":"5","key":"1871_CR3","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/ijms19051477","volume":"19","author":"D Aldinucci","year":"2018","unstructured":"Aldinucci D, Casagrande N (2018) Inhibition of the CCL5\/CCR5 axis against the progression of gastric cancer. Int J Mol Sci 19(5):1477. https:\/\/doi.org\/10.3390\/ijms19051477","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1871_CR4","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.4049\/jimmunol.173.5.3287","volume":"173","author":"HMS Algood","year":"2004","unstructured":"Algood HMS, Flynn JL (2004) CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J Immunol 173(5):3287\u20133296. https:\/\/doi.org\/10.4049\/jimmunol.173.5.3287","journal-title":"J Immunol"},{"key":"1871_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coviro.2015.06.007","volume":"14","author":"K Allers","year":"2015","unstructured":"Allers K, Schneider T (2015) CCR5\u039432 mutation and HIV infection: basis for curative HIV therapy. Curr Opin Virol 14:24\u201329. https:\/\/doi.org\/10.1016\/j.coviro.2015.06.007","journal-title":"Curr Opin Virol"},{"issue":"5","key":"1871_CR6","doi-asserted-by":"publisher","first-page":"1012211","DOI":"10.1371\/journal.ppat.1012211","volume":"20","author":"SL Amorim","year":"2024","unstructured":"Amorim SL, Farias AC, Lombana GC, Beiting D, Novais F, Carvalho PL, Carvalho ME, Scott P (2024) CCR5 promotes the migration of pathological CD8+ T cells to the leishmanial lesions. PLoS Pathog 20(5):1012211. https:\/\/doi.org\/10.1371\/journal.ppat.1012211","journal-title":"PLoS Pathog"},{"issue":"3","key":"1871_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1006\/frne.2001.0214","volume":"22","author":"A Bajetto","year":"2001","unstructured":"Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001) Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22(3):147\u2013184. https:\/\/doi.org\/10.1006\/frne.2001.0214","journal-title":"Front Neuroendocrinol"},{"key":"1871_CR166","doi-asserted-by":"publisher","unstructured":"Bauss J, Morris M, Shankar R, Olivero R, Buck LN, Stenger CL, Hinds D, Mills J, Eby A, Zagorski JW, Smith C, Cline S, Hartog NL, Chen B, Huss J, Carcillo JA, Rajasekaran S, Bupp CP, Prokop JW (2021) CCR5 and biological complexity: the need for data integration and educational materials to address genetic\/biological reductionism at the interface of ethical, legal, and social implications. Front Immunol 12:790041. https:\/\/doi.org\/10.3389\/fimmu.2021.790041","DOI":"10.3389\/fimmu.2021.790041"},{"issue":"11","key":"1871_CR8","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1172\/JCI41732","volume":"120","author":"M-L Berres","year":"2010","unstructured":"Berres M-L, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE (2010) Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 120(11):4129\u20134140. https:\/\/doi.org\/10.1172\/JCI41732","journal-title":"J Clin Invest"},{"issue":"1","key":"1871_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/138945006775270196","volume":"7","author":"K Biber","year":"2006","unstructured":"Biber K, de Jong E, van Weering H, Boddeke H (2006) Chemokines and their receptors in central nervous system disease. Curr Drug Targets 7(1):29\u201346. https:\/\/doi.org\/10.2174\/138945006775270196","journal-title":"Curr Drug Targets"},{"issue":"6","key":"1871_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood.V94.6.1899","volume":"94","author":"C Blanpain","year":"1999","unstructured":"Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, Vassart G, Doms RW, Parmentier M (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94(6):1899\u20131905","journal-title":"Blood"},{"issue":"26","key":"1871_CR11","doi-asserted-by":"publisher","first-page":"23795","DOI":"10.1074\/jbc.M100583200","volume":"276","author":"C Blanpain","year":"2001","unstructured":"Blanpain C, Wittamer V, Vanderwinden JM, Boom A, Renneboog B, Lee B, Le Poul E, El Asmar L, Govaerts C, Vassart G, Doms RW, Parmentier M (2001) Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways. J Biol Chem 276(26):23795\u201323804. https:\/\/doi.org\/10.1074\/jbc.M100583200","journal-title":"J Biol Chem"},{"issue":"5","key":"1871_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14728222.2024.2366880","volume":"28","author":"VD Brata","year":"2024","unstructured":"Brata VD, Tacke F (2024) Fatty liver disease: time to target CCR5? Expert Opin Ther Targets 28(5):335\u2013339. https:\/\/doi.org\/10.1080\/14728222.2024.2366880","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"1871_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/00003088-200948040-00001","volume":"48","author":"KC Brown","year":"2009","unstructured":"Brown KC, Paul S, Kashuba ADM (2009) Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 48(4):211\u2013241. https:\/\/doi.org\/10.2165\/00003088-200948040-00001","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1871_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1053\/gast.2001.22432a","volume":"120","author":"D Buzoni-Gatel","year":"2001","unstructured":"Buzoni-Gatel D, Debbabi H, Mennechet FJ, Martin V, Lepage AC, Schwartzman JD, Kasper LH (2001) Murine ileitis after intracellular parasite infection is controlled by TGF-beta-producing intraepithelial lymphocytes. Gastroenterology 120(4):914\u2013924. https:\/\/doi.org\/10.1053\/gast.2001.22432a","journal-title":"Gastroenterology"},{"issue":"15","key":"1871_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2165\/00003495-200767150-00010","volume":"67","author":"NJ Carter","year":"2007","unstructured":"Carter NJ, Keating GM (2007) Maraviroc. Drugs 67(15):2277\u20132288. https:\/\/doi.org\/10.2165\/00003495-200767150-00010","journal-title":"Drugs"},{"issue":"4","key":"1871_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.2109","volume":"16","author":"CC Carter","year":"2010","unstructured":"Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J, Bixby D, Savona MR, Collins KL (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16(4):446\u2013451. https:\/\/doi.org\/10.1038\/nm.2109","journal-title":"Nat Med"},{"issue":"1","key":"1871_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.brainresrev.2004.07.021","volume":"48","author":"L Cartier","year":"2005","unstructured":"Cartier L, Hartley O, Dubois-Dauphin M, Krause K-H (2005) Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Rev 48(1):16\u201342. https:\/\/doi.org\/10.1016\/j.brainresrev.2004.07.021","journal-title":"Brain Res Rev"},{"issue":"4","key":"1871_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/J.JINF.2012.05.008","volume":"65","author":"MM Caseiro","year":"2012","unstructured":"Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W, Dunkle LM, Vilchez RA, Zeinecker J (2012) Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. J Infect 65(4):326\u2013335. https:\/\/doi.org\/10.1016\/J.JINF.2012.05.008","journal-title":"J Infect"},{"issue":"5","key":"1871_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s0092-8674(00)81430-0","volume":"93","author":"DC Chan","year":"1998","unstructured":"Chan DC, Kim PS (1998) HIV entry and its inhibition. Cell 93(5):681\u2013684. https:\/\/doi.org\/10.1016\/s0092-8674(00)81430-0","journal-title":"Cell"},{"issue":"2","key":"1871_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89(2):263\u2013273. https:\/\/doi.org\/10.1016\/s0092-8674(00)80205-6","journal-title":"Cell"},{"key":"1871_CR163","doi-asserted-by":"publisher","unstructured":"Chang XL, Wu HL, Webb GM, Tiwary M, Hughes C, Reed JS, Hwang J, Waytashek C, Boyle C, Pessoa C, Sylwester AW, Morrow D, Belica K, Fischer M, Kelly S, Pourhassan N, Bochart RM, Smedley J, Recknor CP, Hansen SG, Sacha JB (2021) CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Front Immunol. 12:794638. https:\/\/doi.org\/10.3389\/fimmu.2021.794638","DOI":"10.3389\/fimmu.2021.794638"},{"issue":"1","key":"1871_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jlb.60.1.147","volume":"60","author":"C Combadiere","year":"1996","unstructured":"Combadiere C, Ahuja SK, Tiffany HL, Murphy PM (1996) Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol 60(1):147\u2013152. https:\/\/doi.org\/10.1002\/jlb.60.1.147","journal-title":"J Leukoc Biol"},{"issue":"29","key":"1871_CR22","doi-asserted-by":"publisher","first-page":"10101","DOI":"10.1073\/pnas.0804286105","volume":"105","author":"RL Contento","year":"2008","unstructured":"Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, Viola A (2008) CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci U S A 105(29):10101\u201310106. https:\/\/doi.org\/10.1073\/pnas.0804286105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1871_CR23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/QAI.0b013e3181c9caac","volume":"53","author":"KW Crawford","year":"2010","unstructured":"Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C (2010) Pharmacokinetic\/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). J Acquired Immune Deficiency Syndromes (1999) 53(5):598\u2013605. https:\/\/doi.org\/10.1097\/QAI.0b013e3181c9caac","journal-title":"J Acquired Immune Deficiency Syndromes (1999)"},{"issue":"1","key":"1871_CR24","doi-asserted-by":"publisher","first-page":"14413","DOI":"10.1038\/s41598-017-12612-z","volume":"7","author":"W Dampier","year":"2017","unstructured":"Dampier W, Sullivan NT, Chung C-H, Mell JC, Nonnemacher MR, Wigdahl B (2017) Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. Sci Rep 7(1):14413. https:\/\/doi.org\/10.1038\/s41598-017-12612-z","journal-title":"Sci Rep"},{"issue":"10","key":"1871_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0091270008322178","volume":"48","author":"JF Demarest","year":"2008","unstructured":"Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC (2008) In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of aplaviroc. J Clin Pharmacol 48(10):1179\u20131188. https:\/\/doi.org\/10.1177\/0091270008322178","journal-title":"J Clin Pharmacol"},{"issue":"6069","key":"1871_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1126\/science.1215670","volume":"335","author":"D Deng","year":"2012","unstructured":"Deng D, Yan C, Pan X, Mahfouz M, Wang J, Zhu J-K, Shi Y, Yan N (2012) Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 335(6069):720\u2013723. https:\/\/doi.org\/10.1126\/science.1215670","journal-title":"Science"},{"issue":"2","key":"1871_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2710.2008.00978.x","volume":"34","author":"H Dhami","year":"2009","unstructured":"Dhami H, Fritz CE, Gankin B, Pak SH, Yi W, Seya M-J, Raffa RB, Nagar S (2009a) The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J Clin Pharm Ther 34(2):147\u2013160. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00978.x","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1871_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.critrevonc.2010.07.006","volume":"79","author":"UM Domanska","year":"2011","unstructured":"Domanska UM, Kruizinga RC, den Dunnen WFA, Timmer-Bosscha H, de Vries EGE, Walenkamp AME (2011) The chemokine network, a newly discovered target in high grade gliomas. Crit Rev Oncol Hematol 79(2):154\u2013163. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.07.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1871_CR29","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49(11):4721\u20134732. https:\/\/doi.org\/10.1128\/AAC.49.11.4721-4732.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1871_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc2069","volume":"7","author":"RT Dorsam","year":"2007","unstructured":"Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7(2):79\u201394. https:\/\/doi.org\/10.1038\/nrc2069","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1871_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12977-024-00634-1","volume":"21","author":"N Faivre","year":"2024","unstructured":"Faivre N, Verollet C, Dumas F (2024) The chemokine receptor CCR5: multi-faceted hook for HIV-1. Retrovirology 21(1):2. https:\/\/doi.org\/10.1186\/s12977-024-00634-1","journal-title":"Retrovirology"},{"issue":"11","key":"1871_CR32","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm1319","volume":"11","author":"G F\u00e4tkenheuer","year":"2005","unstructured":"F\u00e4tkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AIM, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11(11):1170\u20131172. https:\/\/doi.org\/10.1038\/nm1319","journal-title":"Nat Med"},{"key":"1871_CR165","doi-asserted-by":"publisher","unstructured":"Ferrero MR, Tavares LP, Garcia CC (2022) The Dual Role of CCR5 in the Course of Influenza Infection: Exploring Treatment Opportunities. Front Immunol 12:826621. https:\/\/doi.org\/10.3389\/fimmu.2021.826621","DOI":"10.3389\/fimmu.2021.826621"},{"key":"1871_CR33","doi-asserted-by":"publisher","unstructured":"Flanagan CA (2014) Receptor conformation and constitutive activity in CCR5 chemokine receptor function and HIV infection (pp. 215\u2013263). https:\/\/doi.org\/10.1016\/B978-0-12-417197-8.00008-0","DOI":"10.1016\/B978-0-12-417197-8.00008-0"},{"key":"1871_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/AR3685","author":"DL Fleishaker","year":"2012","unstructured":"Fleishaker DL, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG (2012) Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/AR3685","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1871_CR35","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1124\/dmd.107.017517","volume":"35","author":"A Ghosal","year":"2007","unstructured":"Ghosal A, Ramanathan R, Yuan Y, Hapangama N, Chowdhury SK, Kishnani NS, Alton KB (2007) Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 35(12):2186\u20132195. https:\/\/doi.org\/10.1124\/dmd.107.017517","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1871_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20051970","volume":"203","author":"WG Glass","year":"2006","unstructured":"Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM (2006) Ccr5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203(1):35\u201340. https:\/\/doi.org\/10.1084\/jem.20051970","journal-title":"J Exp Med"},{"issue":"10","key":"1871_CR37","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1084\/jem.20070657","volume":"204","author":"TJ Guzik","year":"2007","unstructured":"Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the T cell in the genesis of angiotensin II\u2013induced hypertension and vascular dysfunction. J Exp Med 204(10):2449\u20132460. https:\/\/doi.org\/10.1084\/jem.20070657","journal-title":"J Exp Med"},{"key":"1871_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/J.EJCA.2022.03.017","volume":"167","author":"GM Haag","year":"2022","unstructured":"Haag GM, Springfeld C, Gr\u00fcn B, Apostolidis L, Zsch\u00e4bitz S, Dietrich M, Berger AK, Weber TF, Zoernig I, Schaaf M, Waberer L, M\u00fcller DW, Al-Batran SE, Halama N, Jaeger D (2022) Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer \u2013 The PICCASSO phase I trial. Eur J Cancer 167:112\u2013122. https:\/\/doi.org\/10.1016\/J.EJCA.2022.03.017","journal-title":"Eur J Cancer"},{"key":"1871_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells12182237","author":"R Hamid","year":"2023","unstructured":"Hamid R, Alaziz M, Mahal AS, Ashton AW, Halama N, Jaeger D, Jiao X, Pestell RG (2023) The role and therapeutic targeting of CCR5 in breast cancer. Cells. https:\/\/doi.org\/10.3390\/cells12182237","journal-title":"Cells"},{"issue":"10","key":"1871_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F (2023) Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol 20(10):633\u2013646. https:\/\/doi.org\/10.1038\/s41575-023-00807-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"51","key":"1871_CR41","doi-asserted-by":"publisher","first-page":"20476","DOI":"10.1073\/pnas.0810843106","volume":"105","author":"A Heredia","year":"2008","unstructured":"Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR (2008) Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A 105(51):20476\u201320481. https:\/\/doi.org\/10.1073\/pnas.0810843106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1871_CR42","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1093\/nar\/gks1446","volume":"41","author":"M Holkers","year":"2013","unstructured":"Holkers M, Maggio I, Liu J, Janssen JM, Miselli F, Mussolino C, Recchia A, Cathomen T, Gon\u00e7alves MAFV (2013) Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res 41(5):e63\u2013e63. https:\/\/doi.org\/10.1093\/nar\/gks1446","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1871_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0167-5699(94)90314-X","volume":"15","author":"R Horuk","year":"1994","unstructured":"Horuk R (1994) The interleukin-8-receptor family: from chemokines to malaria. Immunol Today 15(4):169\u2013174. https:\/\/doi.org\/10.1016\/0167-5699(94)90314-X","journal-title":"Immunol Today"},{"issue":"1","key":"1871_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cyto.2013.01.020","volume":"62","author":"J-Y Hu","year":"2013","unstructured":"Hu J-Y, Zhang J, Cui J-L, Liang X-Y, Lu R, Du G-F, Xu X-Y, Zhou G (2013) Increasing CCL5\/CCR5 on CD4+ T cells in peripheral blood of oral lichen planus. Cytokine 62(1):141\u2013145. https:\/\/doi.org\/10.1016\/j.cyto.2013.01.020","journal-title":"Cytokine"},{"issue":"5750","key":"1871_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1126\/science.1118398","volume":"310","author":"C Huang","year":"2005","unstructured":"Huang C, Tang M, Zhang M-Y, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310(5750):1025\u20131028. https:\/\/doi.org\/10.1126\/science.1118398","journal-title":"Science"},{"issue":"5846","key":"1871_CR46","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1126\/science.1145373","volume":"317","author":"C-C Huang","year":"2007","unstructured":"Huang C-C, Lam SN, Acharya P, Tang M, Xiang S-H, Hussan SS-U, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (New York, Ny) 317(5846):1930\u20131934. https:\/\/doi.org\/10.1126\/science.1145373","journal-title":"Science (New York, Ny)"},{"key":"1871_CR47","doi-asserted-by":"publisher","unstructured":"Hunt, P. W., Shulman, N. S., Hayes, T. L., Dahl, V., Somsouk, M., Funderburg, N. T., McLaughlin, B., Landay, A. L., Adeyemi, O., Gilman, L. E., Clagett, B., Rodriguez, B., Martin, J. N., Schacker, T. W., Shacklett, B. L., Palmer, S., Lederman, M. M., & Deeks, S. G. (2013). The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood, 121(23), 4635\u20134646. https:\/\/doi.org\/10.1182\/BLOOD-2012-06-436345","DOI":"10.1182\/BLOOD-2012-06-436345"},{"issue":"45","key":"1871_CR48","doi-asserted-by":"publisher","first-page":"37503","DOI":"10.1074\/jbc.M500535200","volume":"280","author":"F H\u00fcttenrauch","year":"2005","unstructured":"H\u00fcttenrauch F, Pollok-Kopp B, Oppermann M (2005) G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers. J Biol Chem 280(45):37503\u201337515. https:\/\/doi.org\/10.1074\/jbc.M500535200","journal-title":"J Biol Chem"},{"issue":"2","key":"1871_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1172\/JCI43027","volume":"122","author":"Y Ishida","year":"2012","unstructured":"Ishida Y, Kimura A, Kuninaka Y, Inui M, Matsushima K, Mukaida N, Kondo T (2012) Pivotal role of the CCL5\/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. J Clin Invest 122(2):711\u2013721. https:\/\/doi.org\/10.1172\/JCI43027","journal-title":"J Clin Invest"},{"key":"1871_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835994","volume":"13","author":"AJ Jasinska","year":"2022","unstructured":"Jasinska AJ, Pandrea I, Apetrei C (2022) CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: a prototypic love-hate affair. Front Immunol 13:835994. https:\/\/doi.org\/10.3389\/fimmu.2022.835994","journal-title":"Front Immunol"},{"key":"1871_CR158","doi-asserted-by":"publisher","unstructured":"Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, Tang HY, Speicher DW, Pestell RG (2021) Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 23(1):11. https:\/\/doi.org\/10.1186\/s13058-021-01391-1","DOI":"10.1186\/s13058-021-01391-1"},{"key":"1871_CR155","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/978-1-0716-1979-7_37","volume":"2429","author":"X Jiao","year":"2022","unstructured":"Jiao X, Upadhyaya C, Zhang Z, Zhao J, Li Z, Patel VI, Pestell RG (2022) Assays for the spectrum of circulating tumor cells. Methods Mol Biol 2429:533\u2013545. https:\/\/doi.org\/10.1007\/978-1-0716-1979-7_37","journal-title":"Methods Mol Biol"},{"issue":"7","key":"1871_CR51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/j.1476-5381.2010.01147.x","volume":"162","author":"KL Jones","year":"2011","unstructured":"Jones KL, Maguire JJ, Davenport AP (2011) Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol 162(7):1453\u20131469. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01147.x","journal-title":"Br J Pharmacol"},{"key":"1871_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.42","volume":"4","author":"H Kang","year":"2015","unstructured":"Kang H, Minder P, Park MA, Mesquitta W-T, Torbett BE, Slukvin II (2015) CCR5 disruption in induced pluripotent stem cells using CRISPR\/Cas9 Provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. Molecular Therapy\u2014Nucleic Acids 4:e268. https:\/\/doi.org\/10.1038\/mtna.2015.42","journal-title":"Molecular Therapy\u2014Nucleic Acids"},{"key":"1871_CR161","doi-asserted-by":"publisher","unstructured":"Karuppusamy KV, Demosthenes JP, Venkatesan V, Christopher AC, Babu P, Azhagiri MK, Jacob A, Ramalingam VV, Rangaraj S, Murugesan MK, Marepally SK, Varghese GM, Srivastava A, Kannangai R, Thangavel S (2022) The CCR5 Gene Edited CD34+CD90+ Hematopoietic Stem Cell Population Serves as an Optimal Graft Source for HIV Gene Therapy. Front Immunol. 13:792684. https:\/\/doi.org\/10.3389\/fimmu.2022.792684","DOI":"10.3389\/fimmu.2022.792684"},{"issue":"6","key":"1871_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0020049","volume":"2","author":"IA Khan","year":"2006","unstructured":"Khan IA, Thomas SY, Moretto MM, Lee FS, Islam SA, Combe C, Schwartzman JD, Luster AD (2006) CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2(6):e49. https:\/\/doi.org\/10.1371\/journal.ppat.0020049","journal-title":"PLoS Pathog"},{"issue":"2","key":"1871_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/524709","volume":"197","author":"E Kindberg","year":"2008","unstructured":"Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, Lundkvist A, Svensson L (2008) A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 197(2):266\u2013269. https:\/\/doi.org\/10.1086\/524709","journal-title":"J Infect Dis"},{"issue":"1","key":"1871_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033583510000089","volume":"43","author":"A Klug","year":"2010","unstructured":"Klug A (2010) The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation. Q Rev Biophys 43(1):1\u201321. https:\/\/doi.org\/10.1017\/S0033583510000089","journal-title":"Q Rev Biophys"},{"issue":"11","key":"1871_CR56","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1517\/13543780903357478","volume":"18","author":"T Kmmerle","year":"2009","unstructured":"Kmmerle T, Lehmann C, Hartmann P, Wyen C, F\u00e4tkenheuer G (2009) Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opin Investig Drugs 18(11):1773\u20131785. https:\/\/doi.org\/10.1517\/13543780903357478","journal-title":"Expert Opin Investig Drugs"},{"issue":"35","key":"1871_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021360","volume":"99","author":"P Kumar","year":"2020","unstructured":"Kumar P, Aridoss S, Mathiyazhakan M, Balasubramanian G, Jaganathasamy N, Natesan M, V M P, David JK, Rajan S, Adhikary R, Arumugam E (2020) Substance use and risk of HIV infection among men who have sex with men in India: analysis of national IBBS data, India. Medicine (Baltimore) 99(35):e21360. https:\/\/doi.org\/10.1097\/MD.0000000000021360","journal-title":"Medicine (Baltimore)"},{"key":"1871_CR164","doi-asserted-by":"publisher","unstructured":"Kulmann-Leal B, Ellwanger JH, Chies JAB (2021) CCR5\u039432 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population. Front Immunol. 12:758358. https:\/\/doi.org\/10.3389\/fimmu.2021.758358","DOI":"10.3389\/fimmu.2021.758358"},{"issue":"7","key":"1871_CR58","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2004-10-4166","volume":"106","author":"HKW Law","year":"2005","unstructured":"Law HKW, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, Nicholls JM, Peiris JSM, Lau YL (2005a) Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106(7):2366\u20132374. https:\/\/doi.org\/10.1182\/blood-2004-10-4166","journal-title":"Blood"},{"issue":"7","key":"1871_CR59","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.296.7.815","volume":"296","author":"MM Lederman","year":"2006","unstructured":"Lederman MM, Penn-Nicholson A, Cho M, Mosier D (2006) Biology of CCR5 and its role in HIV infection and treatment. JAMA 296(7):815\u2013826. https:\/\/doi.org\/10.1001\/jama.296.7.815","journal-title":"JAMA"},{"key":"1871_CR60","doi-asserted-by":"publisher","first-page":"204020662110303","DOI":"10.1177\/20402066211030380","volume":"29","author":"ME Lewis","year":"2021","unstructured":"Lewis ME, Simpson P, Mori J, Jubb B, Sullivan J, McFadyen L, van der Ryst E, Craig C, Robertson DL, Westby M (2021) V3-loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens. Antivir Chem Chemother 29:20402066211030380. https:\/\/doi.org\/10.1177\/20402066211030380","journal-title":"Antivir Chem Chemother"},{"issue":"1","key":"1871_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther 5(1):1. https:\/\/doi.org\/10.1038\/s41392-019-0089-y","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1871_CR62","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.yexcr.2011.01.009","volume":"317","author":"JK Lim","year":"2011","unstructured":"Lim JK, Murphy PM (2011) Chemokine control of West Nile virus infection. Exp Cell Res 317(5):569\u2013574. https:\/\/doi.org\/10.1016\/j.yexcr.2011.01.009","journal-title":"Exp Cell Res"},{"issue":"3","key":"1871_CR63","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s0092-8674(00)80110-5","volume":"86","author":"R Liu","year":"1996","unstructured":"Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3):367\u2013377. https:\/\/doi.org\/10.1016\/s0092-8674(00)80110-5","journal-title":"Cell"},{"issue":"1\u20132","key":"1871_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11010-018-3443-4","volume":"453","author":"F Liu","year":"2019","unstructured":"Liu F, Zhao Y, Lu J, Chen S, Zhang X, Mao W (2019) Hyperoside inhibits proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae. Mol Cell Biochem 453(1\u20132):179\u2013186. https:\/\/doi.org\/10.1007\/s11010-018-3443-4","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"1871_CR65","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1074\/jbc.M005652200","volume":"276","author":"P Loetscher","year":"2001","unstructured":"Loetscher P, Pellegrino A, Gong J-H, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 276(5):2986\u20132991. https:\/\/doi.org\/10.1074\/jbc.M005652200","journal-title":"J Biol Chem"},{"issue":"2","key":"1871_CR66","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/v2020574","volume":"2","author":"L Lopalco","year":"2010","unstructured":"Lopalco L (2010) CCR5: from natural resistance to a new anti-HIV strategy. Viruses 2(2):574\u2013600. https:\/\/doi.org\/10.3390\/v2020574","journal-title":"Viruses"},{"issue":"1","key":"1871_CR67","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/s41598-017-02634-y","volume":"7","author":"MR L\u00f3pez-Huertas","year":"2017","unstructured":"L\u00f3pez-Huertas MR, Jim\u00e9nez-Tormo L, Madrid-Elena N, Guti\u00e9rrez C, Rodr\u00edguez-Mora S, Coiras M, Alcam\u00ed J, Moreno S (2017) The CCR5-antagonist maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist bryostatin-1. Sci Rep 7(1):2385. https:\/\/doi.org\/10.1038\/s41598-017-02634-y","journal-title":"Sci Rep"},{"issue":"16","key":"1871_CR68","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.1128\/JVI.78.16.8654-8662.2004","volume":"78","author":"K Maeda","year":"2004","unstructured":"Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine\/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78(16):8654\u20138662. https:\/\/doi.org\/10.1128\/JVI.78.16.8654-8662.2004","journal-title":"J Virol"},{"issue":"6069","key":"1871_CR69","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1126\/science.1216211","volume":"335","author":"AN-S Mak","year":"2012","unstructured":"Mak AN-S, Bradley P, Cernadas RA, Bogdanove AJ, Stoddard BL (2012) The crystal structure of TAL effector PthXo1 bound to its DNA target. Science 335(6069):716\u2013719. https:\/\/doi.org\/10.1126\/science.1216211","journal-title":"Science"},{"issue":"22","key":"1871_CR70","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1016\/j.febslet.2009.10.061","volume":"583","author":"H Makinoshima","year":"2009","unstructured":"Makinoshima H, Dezawa M (2009) Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. FEBS Lett 583(22):3697\u20133703. https:\/\/doi.org\/10.1016\/j.febslet.2009.10.061","journal-title":"FEBS Lett"},{"key":"1871_CR167","doi-asserted-by":"publisher","unstructured":"Mamtani M, Mummidi S, Ramsuran V, Pham MH, Maldonado R, Begum K, Valera MS, Sanchez R, Castiblanco J, Kulkarni H, Ndung'u T, He W, Anaya JM, Ahuja SK (2011) Influence of variations in CCL3L1 and CCR5 on tuberculosis in a northwestern Colombian population. J Infect Dis 203(11):1590-1594. https:\/\/doi.org\/10.1093\/infdis\/jir145","DOI":"10.1093\/infdis\/jir145"},{"issue":"1","key":"1871_CR71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ng0597-100","volume":"16","author":"JJ Martinson","year":"1997","unstructured":"Martinson JJ, Chapman NH, Rees DC, Liu Y-T, Clegg JB (1997) Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 16(1):100\u2013103. https:\/\/doi.org\/10.1038\/ng0597-100","journal-title":"Nat Genet"},{"key":"1871_CR72","doi-asserted-by":"publisher","first-page":"30802","DOI":"10.1038\/srep30802","volume":"6","author":"A Mencarelli","year":"2016","unstructured":"Mencarelli A, Cipriani S, Francisci D, Santucci L, Baldelli F, Distrutti E, Fiorucci S (2016) Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci Rep 6:30802. https:\/\/doi.org\/10.1038\/srep30802","journal-title":"Sci Rep"},{"issue":"6","key":"1871_CR73","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.4049\/jimmunol.168.6.2988","volume":"168","author":"FJD Mennechet","year":"2002","unstructured":"Mennechet FJD, Kasper LH, Rachinel N, Li W, Vandewalle A, Buzoni-Gatel D (2002) Lamina propria CD4+ T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen. J Immunol 168(6):2988\u20132996. https:\/\/doi.org\/10.4049\/jimmunol.168.6.2988","journal-title":"J Immunol"},{"issue":"5","key":"1871_CR74","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1096\/fj.201500088R","volume":"30","author":"TP Mikolajczyk","year":"2016","unstructured":"Mikolajczyk TP, Nosalski R, Szczepaniak P, Budzyn K, Osmenda G, Skiba D, Sagan A, Wu J, Vinh A, Marvar PJ, Guzik B, Podolec J, Drummond G, Lob HE, Harrison DG, Guzik TJ (2016) Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension. FASEB J 30(5):1987\u20131999. https:\/\/doi.org\/10.1096\/fj.201500088R","journal-title":"FASEB J"},{"key":"1871_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.816515","author":"H Mohamed","year":"2022","unstructured":"Mohamed H, Gurrola T, Berman R, Collins M, Sariyer IK, Nonnemacher MR, Wigdahl B (2022a) Targeting CCR5 as a component of an HIV-1 therapeutic strategy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.816515","journal-title":"Front Immunol"},{"key":"1871_CR157","doi-asserted-by":"publisher","unstructured":"Mohamed H, Gurrola T, Berman R, Collins M, Sariyer IK, Nonnemacher MR, Wigdahl B (2022b) Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Front Immunol. 12:816515. https:\/\/doi.org\/10.3389\/fimmu.2021.816515","DOI":"10.3389\/fimmu.2021.816515"},{"issue":"2","key":"1871_CR76","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tube.2010.02.002","volume":"90","author":"M M\u00f6ller","year":"2010","unstructured":"M\u00f6ller M, Hoal EG (2010) Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis 90(2):71\u201383. https:\/\/doi.org\/10.1016\/j.tube.2010.02.002","journal-title":"Tuberculosis"},{"issue":"12","key":"1871_CR77","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1111\/trf.13816","volume":"56","author":"MM Morar","year":"2016","unstructured":"Morar MM, Pitman JP, McFarland W, Bloch EM (2016) The contribution of unsafe blood transfusion to human immunodeficiency virus incidence in sub-Saharan Africa: reexamination of the 5% to 10% convention. Transfusion 56(12):3121\u20133132. https:\/\/doi.org\/10.1111\/trf.13816","journal-title":"Transfusion"},{"issue":"1","key":"1871_CR78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0031-6997(24)01439-X","volume":"52","author":"PM Murphy","year":"2000","unstructured":"Murphy PM, Baggiolini M, Charo IF, H\u00e9bert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52(1):145\u2013176","journal-title":"Pharmacol Rev"},{"issue":"13","key":"1871_CR79","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1128\/JVI.00277-15","volume":"89","author":"R Myburgh","year":"2015","unstructured":"Myburgh R, Ivic S, Pepper MS, Gers-Huber G, Li D, Audig\u00e9 A, Rochat M-A, Jaquet V, Regenass S, Manz MG, Salmon P, Krause K-H, Speck RF (2015) Lentivector knockdown of CCR5 in hematopoietic stem and progenitor cells confers functional and persistent HIV-1 resistance in humanized mice. J Virol 89(13):6761\u20136772. https:\/\/doi.org\/10.1128\/JVI.00277-15","journal-title":"J Virol"},{"issue":"1","key":"1871_CR80","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1038\/s41598-019-41080-w","volume":"9","author":"H Nakata","year":"2019","unstructured":"Nakata H, Maeda K, Das D, Chang SB, Matsuda K, Rao KV, Harada S, Yoshimura K, Ghosh AK, Mitsuya H (2019a) Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s. Sci Rep 9(1):4828. https:\/\/doi.org\/10.1038\/s41598-019-41080-w","journal-title":"Sci Rep"},{"issue":"25","key":"1871_CR81","doi-asserted-by":"publisher","first-page":"17478","DOI":"10.1074\/jbc.274.25.17478","volume":"274","author":"RJ Nibbs","year":"1999","unstructured":"Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ (1999) LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 274(25):17478\u201317483. https:\/\/doi.org\/10.1074\/jbc.274.25.17478","journal-title":"J Biol Chem"},{"issue":"4","key":"1871_CR82","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00430-007-0046-1","volume":"196","author":"L Nigro","year":"2007","unstructured":"Nigro L, Rizzo ML, Vancheri C, La Rosa R, Mastruzzo C, Tomaselli V, Ragusa A, Manuele R, Cacopardo B (2007) CCR5 and CCR3 expression on T CD3+ lymphocytes from HIV\/Leishmania co-infected subjects. Med Microbiol Immunol 196(4):253\u2013255. https:\/\/doi.org\/10.1007\/s00430-007-0046-1","journal-title":"Med Microbiol Immunol"},{"issue":"11","key":"1871_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030339","volume":"3","author":"J Novembre","year":"2005","unstructured":"Novembre J, Galvani AP, Slatkin M (2005) The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol 3(11):e339. https:\/\/doi.org\/10.1371\/journal.pbio.0030339","journal-title":"PLoS Biol"},{"key":"1871_CR84","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ceb.2014.01.005","volume":"27","author":"M O\u2019Hayre","year":"2014","unstructured":"O\u2019Hayre M, Degese MS, Gutkind JS (2014) Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol 27:126\u2013135. https:\/\/doi.org\/10.1016\/j.ceb.2014.01.005","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"1871_CR85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicol Pharmacol: RTP 32(1):56\u201367. https:\/\/doi.org\/10.1006\/rtph.2000.1399","journal-title":"Regulatory Toxicol Pharmacol: RTP"},{"issue":"11","key":"1871_CR86","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cellsig.2004.04.007","volume":"16","author":"M Oppermann","year":"2004","unstructured":"Oppermann M (2004) Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 16(11):1201\u20131210. https:\/\/doi.org\/10.1016\/j.cellsig.2004.04.007","journal-title":"Cell Signal"},{"issue":"12","key":"1871_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260941","volume":"16","author":"D Os\u00f3rio","year":"2021","unstructured":"Os\u00f3rio D, Munyangaju I, Nacarapa E, Muhiwa A, Nhangave AV, Ramos JM (2021) Mother-to-child transmission of HIV infection and its associated factors in the district of Bilene, Gaza Province-Mozambique. PLoS ONE 16(12):e0260941. https:\/\/doi.org\/10.1371\/journal.pone.0260941","journal-title":"PLoS ONE"},{"issue":"10","key":"1871_CR88","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1021\/jm060009x","volume":"49","author":"A Palani","year":"2006","unstructured":"Palani A, Tagat JR (2006) Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. J Med Chem 49(10):2851\u20132857. https:\/\/doi.org\/10.1021\/jm060009x","journal-title":"J Med Chem"},{"issue":"21","key":"1871_CR89","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1021\/jm015526o","volume":"44","author":"A Palani","year":"2001","unstructured":"Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM (2001) Discovery of 4-[( Z )-(4-Bromophenyl)- (ethoxyimino)methyl]-1\u2018-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4\u2018-methyl-1,4\u2018- bipiperidine N -Oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 44(21):3339\u20133342. https:\/\/doi.org\/10.1021\/jm015526o","journal-title":"J Med Chem"},{"key":"1871_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","volume":"103","author":"BK Patterson","year":"2021","unstructured":"Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O\u2019Halloran JA, Mudd PA, Akalin E, Ndhlovu LC, Sacha JB (2021) Ccr5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis 103:25\u201332. https:\/\/doi.org\/10.1016\/j.ijid.2020.10.101","journal-title":"Int J Infect Dis"},{"key":"1871_CR91","doi-asserted-by":"publisher","unstructured":"Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari JP, Pang AP, Sugai C, Francisco EB, Pise A, Rodrigues H, Ryou M, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Sacha JB (2020) Disruption of the CCL5\/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. MedRxiv\u202f: The Preprint Server for Health Sciences. https:\/\/doi.org\/10.1101\/2020.05.02.20084673","DOI":"10.1101\/2020.05.02.20084673"},{"issue":"34","key":"1871_CR92","doi-asserted-by":"publisher","first-page":"31936","DOI":"10.1074\/jbc.M104013200","volume":"276","author":"Y Percherancier","year":"2001","unstructured":"Percherancier Y, Planchenault T, Valenzuela-Fernandez A, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F (2001) Palmitoylation-dependent control of degradation, life span, and membrane expression of the CCR5 receptor. J Biol Chem 276(34):31936\u201331944. https:\/\/doi.org\/10.1074\/jbc.M104013200","journal-title":"J Biol Chem"},{"issue":"7","key":"1871_CR93","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nbt1410","volume":"26","author":"EE Perez","year":"2008","unstructured":"Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee Y-L, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange SJ, Urnov FD, Rebar EJ, Ando D, June CH (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nature Biotechnol 26(7):808\u2013816. https:\/\/doi.org\/10.1038\/nbt1410","journal-title":"Nature Biotechnol"},{"key":"1871_CR94","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.addr.2016.04.027","volume":"103","author":"O Pernet","year":"2016","unstructured":"Pernet O, Yadav SS, An DS (2016) Stem cell-based therapies for HIV\/AIDS. Adv Drug Deliv Rev 103:187\u2013201. https:\/\/doi.org\/10.1016\/j.addr.2016.04.027","journal-title":"Adv Drug Deliv Rev"},{"key":"1871_CR160","doi-asserted-by":"publisher","unstructured":"Picton ACP, Paximadis M, Koor GW, Bharuthram A, Shalekoff S, Lassauniere R, Ive P, Tiemessen CT (2021) Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers. Front Immunol. 12:781263. https:\/\/doi.org\/10.3389\/fimmu.2021.781263","DOI":"10.3389\/fimmu.2021.781263"},{"key":"1871_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1343503","author":"J Rodr\u00edguez","year":"2024","unstructured":"Rodr\u00edguez J, De Santis Ar\u00e9valo J, Dennis VA, Rodr\u00edguez AM, Giambartolomei GH (2024) Bystander activation of microglia by Brucella abortus-infected astrocytes induces neuronal death via IL-6 trans-signaling. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1343503","journal-title":"Front Immunol"},{"issue":"2","key":"1871_CR96","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.qai.0000220021.64115.37","volume":"42","author":"MC Rosario","year":"2006","unstructured":"Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E (2006) A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of Maraviroc. JAIDS J Acquir Immune Defic Syndr 42(2):183\u2013191. https:\/\/doi.org\/10.1097\/01.qai.0000220021.64115.37","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"11","key":"1871_CR97","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nrn2255","volume":"8","author":"W Rost\u00e8ne","year":"2007","unstructured":"Rost\u00e8ne W, Kitabgi P, Parsadaniantz SM (2007) Chemokines: a new class of neuromodulator? Nat Rev Neurosci 8(11):895\u2013903. https:\/\/doi.org\/10.1038\/nrn2255","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"1871_CR98","first-page":"1341","volume":"151","author":"JB Rottman","year":"1997","unstructured":"Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ (1997) Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol 151(5):1341\u20131351","journal-title":"Am J Pathol"},{"issue":"6593","key":"1871_CR99","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/382722a0","volume":"382","author":"M Samson","year":"1996","unstructured":"Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382(6593):722\u2013725. https:\/\/doi.org\/10.1038\/382722a0","journal-title":"Nature"},{"issue":"2","key":"1871_CR100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1084\/jem.174.2.407","volume":"174","author":"QJ Sattentau","year":"1991","unstructured":"Sattentau QJ, Moore JP (1991) Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 174(2):407\u2013415. https:\/\/doi.org\/10.1084\/jem.174.2.407","journal-title":"J Exp Med"},{"issue":"3","key":"1871_CR101","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1086\/600399","volume":"49","author":"J Schulze zur Wiesch","year":"2009","unstructured":"Schulze zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, Hauber J, van Lunzen J (2009) Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 49(3):466\u2013472. https:\/\/doi.org\/10.1086\/600399","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1871_CR102","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41434-021-00271-9","volume":"28","author":"LI Schwarze","year":"2021","unstructured":"Schwarze LI, G\u0142\u00f3w D, Sonntag T, Uhde A, Fehse B (2021a) Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene Ther 28(9):588\u2013601. https:\/\/doi.org\/10.1038\/s41434-021-00271-9","journal-title":"Gene Ther"},{"issue":"9","key":"1871_CR103","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41434-021-00259-5","volume":"28","author":"LI Schwarze","year":"2021","unstructured":"Schwarze LI, Sonntag T, Wild S, Schmitz S, Uhde A, Fehse B (2021b) Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients. Gene Ther 28(9):572\u2013587. https:\/\/doi.org\/10.1038\/s41434-021-00259-5","journal-title":"Gene Ther"},{"key":"1871_CR162","doi-asserted-by":"publisher","unstructured":"Scheller SH, Rashad Y, Saleh FM, Willingham KA, Reilich A, Lin D, Izadpanah R, Alt EU, Braun SE (2022) Biallelic, Selectable, Knockin Targeting of CCR5 via CRISPR-Cas9 Mediated Homology Directed Repair Inhibits HIV-1 Replication. Front Immunol. 13:821190. https:\/\/doi.org\/10.3389\/fimmu.2022.821190","DOI":"10.3389\/fimmu.2022.821190"},{"issue":"17","key":"1871_CR104","doi-asserted-by":"publisher","first-page":"11031","DOI":"10.1073\/pnas.172380899","volume":"99","author":"C Seibert","year":"2002","unstructured":"Seibert C, Cadene M, Sanfiz A, Chait BT, Sakmar TP (2002) Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence. Proc Natl Acad Sci U S A 99(17):11031\u201311036. https:\/\/doi.org\/10.1073\/pnas.172380899","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1871_CR105","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.21037\/tau-23-540","volume":"12","author":"J Shen","year":"2023","unstructured":"Shen J, Chen C, Chen Z, Gong P, Lee LS, Schmeusser BN, Zhuang Q, Sun Y, Xue D, He X (2023) CCL5 promotes the proliferation and metastasis of bladder cancer via the JAK2\/STAT3 signaling pathway. Transl Androl Urol 12(12):1845\u20131858. https:\/\/doi.org\/10.21037\/tau-23-540","journal-title":"Transl Androl Urol"},{"issue":"12","key":"1871_CR106","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1080\/0036554021000026975","volume":"34","author":"P Skendros","year":"2002","unstructured":"Skendros P, Boura P, Tsantas N, Debre P, Theodorou I (2002) Frequency analysis of the CCR5?32 mutation in patients with brucellosis. Scand J Infect Dis 34(12):944\u2013946. https:\/\/doi.org\/10.1080\/0036554021000026975","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"1871_CR156","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ijc.28962","volume":"136","author":"PN Span","year":"2015","unstructured":"Span PN, Pollakis G, Paxton WA, Sweep FC, Foekens JA, Martens JW, Sieuwerts AM, van Laarhoven HW (2015) Improved metastasisfree survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. Int J Cancer. 136(1):91\u201397. https:\/\/doi.org\/10.1002\/ijc.28962","journal-title":"Int J Cancer."},{"issue":"12","key":"1871_CR108","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","volume":"49","author":"JM Strizki","year":"2005","unstructured":"Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou C-C, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 49(12):4911\u20134919. https:\/\/doi.org\/10.1128\/AAC.49.12.4911-4919.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"1871_CR109","unstructured":"Study Details | Charit\u00e9 trial of cenicriviroc (CVC) treatment for COVID-19 patients | ClinicalTrials.gov. (2025). Retrieved 7 Jul 2025, from https:\/\/clinicaltrials.gov\/study\/NCT04500418"},{"key":"1871_CR110","unstructured":"Study Details | Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects | ClinicalTrials.gov. (2025a). Retrieved 7 Jul 2025, from https:\/\/clinicaltrials.gov\/study\/NCT00098306"},{"key":"1871_CR111","unstructured":"Study Details | Trial of Maraviroc (UK-427,857) in combination with optimized background therapy versus optimized background therapy alone for the treatment of HIV-1 infected subjects | ClinicalTrials.gov. (2025b). Retrieved 7 Jul 2025, from https:\/\/clinicaltrials.gov\/study\/NCT00098722"},{"issue":"12","key":"1871_CR112","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/sj.ejhg.5200568","volume":"8","author":"B Su","year":"2000","unstructured":"Su B, Sun G, Lu D, Xiao J, Hu F, Chakraborty R, Deka R, Jin L (2000) Distribution of three HIV-1 resistance-conferring polymorphisms (SDF1-3\u2032A, CCR2-64I, and CCR5-\u039432) in global populations. Eur J Hum Genet 8(12):975\u2013979. https:\/\/doi.org\/10.1038\/sj.ejhg.5200568","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1871_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0253-7184.55471","volume":"30","author":"PK Surya Rao","year":"2009","unstructured":"Surya Rao PK (2009) CCR5 inhibitors: emerging promising HIV therapeutic strategy. Indian J Sex Transm Dis 30(1):1\u20139. https:\/\/doi.org\/10.4103\/0253-7184.55471","journal-title":"Indian J Sex Transm Dis"},{"issue":"1","key":"1871_CR114","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.antiviral.2011.02.005","volume":"90","author":"V Svicher","year":"2011","unstructured":"Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D\u2019Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF (2011) HIV-1 dual\/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antivir Res 90(1):42\u201353. https:\/\/doi.org\/10.1016\/j.antiviral.2011.02.005","journal-title":"Antivir Res"},{"issue":"2","key":"1871_CR115","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bcp.2009.08.006","volume":"79","author":"C-H Tang","year":"2010","unstructured":"Tang C-H, Yamamoto A, Lin Y-T, Fong Y-C, Tan T-W (2010) Involvement of matrix metalloproteinase-3 in CCL5\/CCR5 pathway of chondrosarcomas metastasis. Biochem Pharmacol 79(2):209\u2013217. https:\/\/doi.org\/10.1016\/j.bcp.2009.08.006","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1871_CR116","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang W-T, Levine BL, June CH (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370(10):901\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa1300662","journal-title":"N Engl J Med"},{"key":"1871_CR117","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144486","author":"P Tebas","year":"2021","unstructured":"Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL (2021) CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI144486","journal-title":"J Clin Invest"},{"issue":"1","key":"1871_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12883-024-03683-3\/FIGURES\/2","volume":"24","author":"O Tene","year":"2024","unstructured":"Tene O, Molad J, Rotschild O, Alpernas A, Hawwari M, Seyman E, Giladi N, Hallevi H, Assayag EB (2024) Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial. BMC Neurol 24(1):1\u20139. https:\/\/doi.org\/10.1186\/S12883-024-03683-3\/FIGURES\/2","journal-title":"BMC Neurol"},{"key":"1871_CR119","unstructured":"Trial | NCT00735072. (2025). Retrieved 7 Jul 2025, from https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT00735072\/"},{"issue":"6605","key":"1871_CR120","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/384184a0","volume":"384","author":"A Trkola","year":"1996","unstructured":"Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP (1996) CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384(6605):184\u2013187. https:\/\/doi.org\/10.1038\/384184a0","journal-title":"Nature"},{"issue":"9","key":"1871_CR121","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1128\/jvi.77.9.5201-5208.2003","volume":"77","author":"F Tsamis","year":"2003","unstructured":"Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77(9):5201\u20135208. https:\/\/doi.org\/10.1128\/jvi.77.9.5201-5208.2003","journal-title":"J Virol"},{"issue":"6822","key":"1871_CR122","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/35057011","volume":"409","author":"R Tupler","year":"2001","unstructured":"Tupler R, Perini G, Green MR (2001) Expressing the human genome. Nature 409(6822):832\u2013833. https:\/\/doi.org\/10.1038\/35057011","journal-title":"Nature"},{"issue":"2","key":"1871_CR123","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cells7020010","volume":"7","author":"F Urusov","year":"2018","unstructured":"Urusov F, Glazkova D, Omelchenko D, Bogoslovskaya E, Tsyganova G, Kersting K, Shipulin G, Pokrovsky V (2018) Optimization of polycistronic anti-CCR5 artificial microRNA leads to improved accuracy of its lentiviral vector transfer and more potent inhibition of HIV-1 in CD4+ T-cells. Cells 7(2):10. https:\/\/doi.org\/10.3390\/cells7020010","journal-title":"Cells"},{"key":"1871_CR124","unstructured":"US10429385B2\u2014Treating conditions associated with sepsis\u2014Google Patents. (2025). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/US10429385B2\/en?oq=US10429385B2"},{"key":"1871_CR125","unstructured":"US10494422B2\u2014CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/US10494422B2\/en?oq=US10494422B2"},{"key":"1871_CR126","unstructured":"US10746745B2\u2014Future cardiac event biomarkers CCL3, CCL5, and CCL18\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/US10746745B2\/en?oq=US10746745B2"},{"key":"1871_CR127","unstructured":"US11045546B1\u2014Methods of treating coronavirus infection\u2014Google Patents. (n.d.). Retrieved July 7, 2025, from https:\/\/patents.google.com\/patent\/US11045546B1\/en?oq=US11045546B1"},{"key":"1871_CR128","unstructured":"US11105805B2\u2014Method for detecting HIV-1 co-receptor tropism\u2014Google Patents. (n.d.). Retrieved July 7, 2025, from https:\/\/patents.google.com\/patent\/US11105805B2\/en?oq=US11105805B2"},{"key":"1871_CR129","unstructured":"US11648267B2\u2014Methods and compositions for gene inactivation\u2014Google Patents. (n.d.). Retrieved July 7, 2025, from https:\/\/patents.google.com\/patent\/US11648267B2\/en?oq=US11648267+%D0%922"},{"key":"1871_CR130","unstructured":"US20240110166A1\u2014Editing of ccr5 receptor gene to protect against hiv infection\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/US20240110166A1\/en?oq=US20240110166A1"},{"key":"1871_CR131","unstructured":"US7862818B2\u2014Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/US7862818B2\/en?oq=US7862818B2"},{"key":"1871_CR132","unstructured":"US8318170B2\u2014Methods for prevention and treatment of inflammation using anti-chemokine antibodies\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/US8318170B2\/en?oq=US8318170B2"},{"issue":"11","key":"1871_CR133","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1136\/ard.2010.131235","volume":"69","author":"AWR Van Kuijk","year":"2010","unstructured":"Van Kuijk AWR, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R, Verschueren PC, Van De Leij C, Maas M, Kraan MC, Tak PP (2010) CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 69(11):2013\u20132016. https:\/\/doi.org\/10.1136\/ard.2010.131235","journal-title":"Ann Rheum Dis"},{"key":"1871_CR159","doi-asserted-by":"publisher","unstructured":"Velasco-Vel\u00e1zquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG (2012) CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72(15):3839-3850. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3917","DOI":"10.1158\/0008-5472.CAN-11-3917"},{"issue":"4","key":"1871_CR134","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1124\/dmd.104.002626","volume":"33","author":"DK Walker","year":"2005","unstructured":"Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman ANR, Smith DA (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33(4):587\u2013595. https:\/\/doi.org\/10.1124\/dmd.104.002626","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1871_CR135","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0049-3848(77)90117-7","volume":"11","author":"DA Walz","year":"1977","unstructured":"Walz DA, Wu VY, de Lamo R, Dene H, McCoy LE (1977) Primary structure of human platelet factor 4. Thromb Res 11(6):893\u2013898. https:\/\/doi.org\/10.1016\/0049-3848(77)90117-7","journal-title":"Thromb Res"},{"key":"1871_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00117","author":"X Wang","year":"2015","unstructured":"Wang X, Hills LB, Huang YH (2015) Lipid and Protein Co-Regulation of PI3K Effectors Akt and Itk in Lymphocytes. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00117","journal-title":"Front Immunol"},{"issue":"9","key":"1871_CR137","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/jop.13087","volume":"49","author":"Y Wang","year":"2020","unstructured":"Wang Y, Du G, Shi L, Shen X, Shen Z, Liu W (2020) Altered expression of CCN1 in oral lichen planus associated with keratinocyte activation and IL-1\u03b2, ICAM1, and CCL5 up-regulation. J Oral Pathol Med 49(9):920\u2013925. https:\/\/doi.org\/10.1111\/jop.13087","journal-title":"J Oral Pathol Med"},{"issue":"10","key":"1871_CR138","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nri2415","volume":"8","author":"C Weber","year":"2008","unstructured":"Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8(10):802\u2013815. https:\/\/doi.org\/10.1038\/nri2415","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1871_CR139","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2005.11.001","volume":"27","author":"TNC Wells","year":"2006","unstructured":"Wells TNC, Power CA, Shaw JP, Proudfoot AEI (2006) Chemokine blockers\u2013therapeutics in the making? Trends Pharmacol Sci 27(1):41\u201347. https:\/\/doi.org\/10.1016\/j.tips.2005.11.001","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"1871_CR140","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1128\/JVI.02006-06","volume":"81","author":"M Westby","year":"2007","unstructured":"Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81(5):2359\u20132371. https:\/\/doi.org\/10.1128\/JVI.02006-06","journal-title":"J Virol"},{"key":"1871_CR141","doi-asserted-by":"publisher","DOI":"10.15406\/moji.2014.01.00022","author":"B Wigdahl","year":"2014","unstructured":"Wigdahl B (2014) HIV excision utilizing CRISPR\/Cas9 technology: attacking the proviral quasispecies in reservoirs to achieve a cure. MOJ Immunol. https:\/\/doi.org\/10.15406\/moji.2014.01.00022","journal-title":"MOJ Immunol"},{"key":"1871_CR142","unstructured":"WO2004031172A1\u2014Piperidine derivatives as ccr5 inhibitors\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/WO2004031172A1\/en?oq=WO2004031172A1"},{"key":"1871_CR143","unstructured":"WO2020181163A1\u2014Lipid-based formulation of cenicriviroc\u2014Google Patents. (n.d.). Retrieved 7 Jul 2025, from https:\/\/patents.google.com\/patent\/WO2020181163A1\/en?oq=WO2020181163A1"},{"issue":"6605","key":"1871_CR144","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/384179a0","volume":"384","author":"L Wu","year":"1996","unstructured":"Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384(6605):179\u2013183. https:\/\/doi.org\/10.1038\/384179a0","journal-title":"Nature"},{"key":"1871_CR145","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cyto.2018.04.027","volume":"110","author":"Y-C Wu","year":"2018","unstructured":"Wu Y-C, Shen Y-C, Chang JW-C, Hsieh J-J, Chu Y, Wang C-H (2018) Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro. Cytokine 110:94\u2013103. https:\/\/doi.org\/10.1016\/j.cyto.2018.04.027","journal-title":"Cytokine"},{"issue":"10","key":"1871_CR146","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/15384047.2017.1373219","volume":"18","author":"T Yang","year":"2017","unstructured":"Yang T, Chen M, Yang X, Zhang X, Zhang Z, Sun Y, Xu B, Hua J, He Z, Song Z (2017) Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5\/CCR5 axis. Cancer Biol Ther 18(10):806\u2013815. https:\/\/doi.org\/10.1080\/15384047.2017.1373219","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"1871_CR147","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1128\/JVI.80.6.2684-2693.2006","volume":"80","author":"Y-T Yen","year":"2006","unstructured":"Yen Y-T, Liao F, Hsiao C-H, Kao C-L, Chen Y-C, Wu-Hsieh BA (2006) Modeling the early events of Severe Acute Respiratory Syndrome coronavirus infection in vitro. J Virol 80(6):2684\u20132693. https:\/\/doi.org\/10.1128\/JVI.80.6.2684-2693.2006","journal-title":"J Virol"},{"key":"1871_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.52","volume":"3","author":"G Yi","year":"2014","unstructured":"Yi G, Choi JG, Bharaj P, Abraham S, Dang Y, Kafri T, Alozie O, Manjunath MN, Shankar P (2014) CCR5 gene editing of resting CD4+ T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice. Molecular Therapy\u2014Nucleic Acids 3:e198. https:\/\/doi.org\/10.1038\/mtna.2014.52","journal-title":"Molecular Therapy\u2014Nucleic Acids"},{"issue":"8","key":"1871_CR149","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2146\/ajhp080206","volume":"66","author":"R Yost","year":"2009","unstructured":"Yost R, Pasquale TR, Sahloff EG (2009) Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health-Syst Pharm 66(8):715\u2013726. https:\/\/doi.org\/10.2146\/ajhp080206","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"1871_CR150","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/hum.2017.032","volume":"29","author":"S Yu","year":"2018","unstructured":"Yu S, Yao Y, Xiao H, Li J, Liu Q, Yang Y, Adah D, Lu J, Zhao S, Qin L, Chen X (2018) Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR\/Cas9 confers resistance to both X4- and R5-tropic human immunodeficiency virus type 1 infection. Hum Gene Ther 29(1):51\u201367. https:\/\/doi.org\/10.1089\/hum.2017.032","journal-title":"Hum Gene Ther"},{"issue":"11","key":"1871_CR151","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1084\/jem.20060956","volume":"203","author":"E Yurchenko","year":"2006","unstructured":"Yurchenko E, Tritt M, Hay V, Shevach EM, Belkaid Y, Piccirillo CA (2006) CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 203(11):2451\u20132460. https:\/\/doi.org\/10.1084\/jem.20060956","journal-title":"J Exp Med"},{"issue":"1","key":"1871_CR152","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","volume":"9","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Lan T, Wei Y, Wei X (2022) CCL5\/CCR5 axis in human diseases and related treatments. Genes Dis 9(1):12\u201327. https:\/\/doi.org\/10.1016\/j.gendis.2021.08.004","journal-title":"Genes Dis"},{"key":"1871_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00146","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Wang Q, Yao J, Zhou X, Zhao J, Zhang X, Dong J, Liao L (2020) Chemokine receptor 5, a double-edged sword in metabolic syndrome and cardiovascular disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2020.00146","journal-title":"Front Pharmacol"},{"issue":"4","key":"1871_CR154","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1034\/j.1601-0825.2001.70408.x","volume":"7","author":"ZZ Zhao","year":"2001","unstructured":"Zhao ZZ, Sugerman PB, Zhou XJ, Walsh LJ, Savage NW (2001) Mast cell degranulation and the role of T cell RANTES in oral lichen planus. Oral Dis 7(4):246\u2013251","journal-title":"Oral Dis"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01871-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:15:52Z","timestamp":1757358952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01871-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":166,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1871"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01871-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors announce that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}